tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agents antinéoplasiques - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
tecentriq solution
hoffmann-la roche limited - atÉzolizumab - solution - 1200mg - atÉzolizumab 1200mg - antineoplastic agents
tecentriq solution
hoffmann-la roche limited - atÉzolizumab - solution - 840mg - atÉzolizumab 840mg - antineoplastic agents
tecentriq 1200 mg/20 ml solution à diluer pour perfusion
roche pharma (schweiz) ag - atezolizumabum - solution à diluer pour perfusion - atezolizumabum 1200 mg, histidinum, acidum aceticum glaciale, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 20 ml. - onkologikum - biotechnologika
tecentriq 840 mg/14 ml solution à diluer pour perfusion
roche pharma (schweiz) ag - atezolizumabum - solution à diluer pour perfusion - atezolizumabum 840 mg, histidinum, acidum aceticum glaciale, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 14 ml. - onkologikum - biotechnologika
tecentriq 1200mg solution injectable pour perfusion
roche pharma (schweiz) ag - atezolizumab - solution injectable pour perfusion - 1200mg - antineoplasiques et immunomodulateurs - antineoplasiques - tecentriq est indiqué pour le traitement des patients atteints d'un cancer du poumon non à petites cellules (cpnpc) localement avancé ou métastatique, après chimiothérapie préalable.
tecentriq 1200 mg concentrat solució perfusió 1 vial
natalizumab elan pharma
elan pharma international ltd. - natalizumab - maladie de crohn - les immunostimulants, - traitement de modérément à sévèrement active de la maladie de crohn pour la réduction des signes et des symptômes, et l'induction et l'entretien de réponse soutenue et de la rémission chez les patients qui n'ont pas répondu malgré une pleine et adéquate cours du traitement avec un corticostéroïde et d'un immunosuppresseur; ou une intolérance ou de contre-indications médicales à ces thérapies.
entyvio subkutan 108 mg injektionslösung in einem fertigpen
takeda pharma ag - vedolizumabum - injektionslösung in einem fertigpen - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - la colite ulcérative, morbus crohn - biotechnologika
entyvio subkutan 108 mg injektionslösung in einer fertigspritze
takeda pharma ag - vedolizumabum - injektionslösung in einer fertigspritze - vedolizumabum 108 mg, acidum citricum monohydricum, natrii citras dihydricus corresp. natrium 1.11 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.68 ml. - la colite ulcérative, morbus crohn - biotechnologika